These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33013676)

  • 1. Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes.
    Camelo-Filho AE; Silva AMS; Estephan EP; Zambon AA; Mendonça RH; Souza PVS; Pinto WBVR; Oliveira ASB; Dangoni-Filho I; Pouza AFP; Valerio BCO; Zanoteli E
    Front Neurol; 2020; 11():1053. PubMed ID: 33013676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience.
    Županić S; Perić Šitum M; Majdak M; Karakaš M; Bašić S; Sporiš D
    Acta Neurol Belg; 2021 Aug; 121(4):1039-1044. PubMed ID: 33797054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis.
    Solé G; Mathis S; Friedman D; Salort-Campana E; Tard C; Bouhour F; Magot A; Annane D; Clair B; Le Masson G; Soulages A; Duval F; Carla L; Violleau MH; Saulnier T; Segovia-Kueny S; Kern L; Antoine JC; Beaudonnet G; Audic F; Kremer L; Chanson JB; Nadaj-Pakleza A; Stojkovic T; Cintas P; Spinazzi M; Foubert-Samier A; Attarian S
    Neurology; 2021 Apr; 96(16):e2109-e2120. PubMed ID: 33568541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and outcomes of patients with myasthenia gravis affected by COVID-19: A single-center study.
    Karimi N; Fatehi F; Okhovat AA; Abdi S; Sinaei F; Sikaroodi H; Vahabi Z; Nafissi S
    Clin Neurol Neurosurg; 2022 Nov; 222():107441. PubMed ID: 36174408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 infection in myasthenia gravis: Clinical course and outcomes.
    Thomas EV; Bou G; Barton S; Hutto S; Garcia-Santibanez R
    Muscle Nerve; 2023 Aug; 68(2):171-175. PubMed ID: 37326164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2003; (2):CD002277. PubMed ID: 12804431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2006 Apr; (2):CD002277. PubMed ID: 16625559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenic Crisis.
    Kirmani JF; Yahia AM; Qureshi AI
    Curr Treat Options Neurol; 2004 Jan; 6(1):3-15. PubMed ID: 14664765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia and the neuromuscular junction.
    Gilhus NE
    Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of prethymectomy plasma exchange on postoperative respiratory function in myasthenia gravis.
    d'Empaire G; Hoaglin DC; Perlo VP; Pontoppidan H
    J Thorac Cardiovasc Surg; 1985 Apr; 89(4):592-6. PubMed ID: 3982061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients.
    Alipour-Faz A; Shojaei M; Peyvandi H; Ramzi D; Oroei M; Ghadiri F; Peyvandi M
    Acta Neurol Belg; 2017 Mar; 117(1):245-249. PubMed ID: 27530310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myasthenia gravis.
    Pourmand R
    Dis Mon; 1997 Feb; 43(2):65-109. PubMed ID: 9118787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 Presentation in Association with Myasthenia Gravis: A Case Report and Review of the Literature.
    Aksoy E; Oztutgan T
    Case Rep Infect Dis; 2020; 2020():8845844. PubMed ID: 32850160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Warming yang and invigorating qi" acupuncture alters acetylcholine receptor expression in the neuromuscular junction of rats with experimental autoimmune myasthenia gravis.
    Huang HP; Pan H; Wang HF
    Neural Regen Res; 2016 Mar; 11(3):465-8. PubMed ID: 27127487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myasthenia gravis and the neuromuscular junction.
    Querol L; Illa I
    Curr Opin Neurol; 2013 Oct; 26(5):459-65. PubMed ID: 23945282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rocuronium vs vecuronium for neuromuscular block during transsternal thymectomy in the patient with myasthenia gravis].
    Cordero Escobar I
    Rev Esp Anestesiol Reanim; 2011 Dec; 58(10):578-82. PubMed ID: 22263401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence.
    Gilhus NE; Hong Y
    Eur J Neurol; 2018 Dec; 25(12):1402-1409. PubMed ID: 30133097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.